Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.
Business & Industry
- AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine
- Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program
- Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
- AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
- Gilead announces results from Phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19
Research & Development
- Official COVID-19 deaths underestimate the full impact of the pandemic
- Local climate unlikely to drive the early COVID-19 pandemic
- Researchers urge clinical trial of blood pressure drug to prevent complication of COVID-19
- Antibody neutralizes SARS and COVID-19 coronaviruses
- Early indicators of vaccine efficacy
- Arthritis drug may improve respiratory function in some patients with severe COVID-19
- Frankfurt researchers discover potential targets for COVID-19 therapy
Conferences & Events
- Pre-filled Syringes San Francisco Conference 2020
- Oligonucleotide Therapeutics and Delivery Conference 2020
- Pre-Filled Syringes West Coast 2021
- Pre-Filled Syringes East Coast Conference 2020
- SMi's 4th Annual Pharmaceutical Microbiology West Coast
- SMi's 20th Annual Pain Therapeutics Conference 2020
- SMi's 3rd Annual Pharmaceutical Microbiology East Coast
Regulatory Affairs
- Global regulators commit to cooperate on observational research in the context of COVID-19
- FDA takes new actions to accelerate development of novel prevention, treatment options for COVID-19
- FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
- FDA reiterates importance of close patient supervision for 'off-label' use of antimalarial drugs
- FDA encourages recovered patients to donate plasma for development of blood-related therapies